LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000829

Predictors of complications after inguinal lymphadenectomy

Identifieur interne : 000829 ( PascalFrancis/Corpus ); précédent : 000828; suivant : 000830

Predictors of complications after inguinal lymphadenectomy

Auteurs : Natalie Gould ; Scott Kamelle ; Todd Tillmanns ; Dennis Scribner ; Michael Gold ; Joan Walker ; Robert Mannel

Source :

Gynecologic oncology [ 0090-8258 ] ; 2001.

RBID : Pascal:01-0470242

Descripteurs français

Pascal (Inist)
- Tumeur maligne, Vulve, Lymphadénectomie, Inguinal, Lymphoedème, Complication, Incidence, Facteur prédictif, Pronostic, Homme, Femelle.

English descriptors

KwdEn :
- Complication, Female, Human, Incidence, Inguinal, Lymphadenectomy, Lymphedema, Malignant tumor, Predictive factor, Prognosis, Vulva.

Abstract

Objective. The aim of this study was to identify predictors of complications in patients undergoing inguinal lymphadenectomy (LND) in the treatment of vulvar carcinoma. Methods. Clinical information was abstracted from records of patients with invasive vulvar cancer. All patients underwent LND. Closed suction drains were placed in groin incisions and removed when output was less than 30 ml/24 h. Associations between variables were studied by X² and t tests. Results. Sixty-seven patients undergoing 112 LND were evaluated. Eighty-eight percent of patients underwent radical vulvar surgery and LND while 12% underwent LND alone. Patients were treated with either unilateral (22) or bilateral (45) LND. Seventy-three percent received extended postoperative prophylactic antibiotics. The median duration of suction drainage was 15 days for one drain and 14 days for two drains. Early postoperative cellulitis (<30 days after surgery) developed in 35.4%, early wound breakdown in 19.4%, early lymphedema in 4.8%, and early lymphocyst formation in 13.1%. Late cellulitis (>30 days after surgery) developed in 22.2%, late wound breakdown in 3.2%, late lymphedema in 29.5%, and late lymphocysts in 5%. Patients developing early cellulitis were more likely to have early wound breakdown (P = <0.001, RR 14.2) or early lymphocyst formation (P = 0.016, RR 7.6). Type of procedure, antibiotic use, need for adjuvant therapy, and duration of suction drainage did not influence early complications. Early complications and management strategies did not predict late complications. Conclusions. Chronic lymphedema occurs in nearly 30% of patients after LND. Late complications after LND were not predicted by early complications. New strategies for prevention of chronic lymphedema are needed.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0090-8258`
A02	`01`			`@0 GYNOA3`
A03		`1`		`@0 Gynecol. oncol.`
A05				`@2 82`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Predictors of complications after inguinal lymphadenectomy`
A11	`01`	`1`		`@1 GOULD (Natalie)`
A11	`02`	`1`		`@1 KAMELLE (Scott)`
A11	`03`	`1`		`@1 TILLMANNS (Todd)`
A11	`04`	`1`		`@1 SCRIBNER (Dennis)`
A11	`05`	`1`		`@1 GOLD (Michael)`
A11	`06`	`1`		`@1 WALKER (Joan)`
A11	`07`	`1`		`@1 MANNEL (Robert)`
A14	`01`			`@1 Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center @2 Oklahoma City, Oklahoma 73190 @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut.`
A20				`@1 329-332`
A21				`@1 2001`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16044 @5 354000099427810190`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 14 ref.`
A47	`01`	`1`		`@0 01-0470242`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Gynecologic oncology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Objective. The aim of this study was to identify predictors of complications in patients undergoing inguinal lymphadenectomy (LND) in the treatment of vulvar carcinoma. Methods. Clinical information was abstracted from records of patients with invasive vulvar cancer. All patients underwent LND. Closed suction drains were placed in groin incisions and removed when output was less than 30 ml/24 h. Associations between variables were studied by X² and t tests. Results. Sixty-seven patients undergoing 112 LND were evaluated. Eighty-eight percent of patients underwent radical vulvar surgery and LND while 12% underwent LND alone. Patients were treated with either unilateral (22) or bilateral (45) LND. Seventy-three percent received extended postoperative prophylactic antibiotics. The median duration of suction drainage was 15 days for one drain and 14 days for two drains. Early postoperative cellulitis (<30 days after surgery) developed in 35.4%, early wound breakdown in 19.4%, early lymphedema in 4.8%, and early lymphocyst formation in 13.1%. Late cellulitis (>30 days after surgery) developed in 22.2%, late wound breakdown in 3.2%, late lymphedema in 29.5%, and late lymphocysts in 5%. Patients developing early cellulitis were more likely to have early wound breakdown (P = <0.001, RR 14.2) or early lymphocyst formation (P = 0.016, RR 7.6). Type of procedure, antibiotic use, need for adjuvant therapy, and duration of suction drainage did not influence early complications. Early complications and management strategies did not predict late complications. Conclusions. Chronic lymphedema occurs in nearly 30% of patients after LND. Late complications after LND were not predicted by early complications. New strategies for prevention of chronic lymphedema are needed.
C02	`01`	`X`		`@0 002B25K`
C03	`01`	`X`	`FRE`	`@0 Tumeur maligne @5 01`
C03	`01`	`X`	`ENG`	`@0 Malignant tumor @5 01`
C03	`01`	`X`	`SPA`	`@0 Tumor maligno @5 01`
C03	`02`	`X`	`FRE`	`@0 Vulve @5 02`
C03	`02`	`X`	`ENG`	`@0 Vulva @5 02`
C03	`02`	`X`	`SPA`	`@0 Vulva @5 02`
C03	`03`	`X`	`FRE`	`@0 Lymphadénectomie @5 03`
C03	`03`	`X`	`ENG`	`@0 Lymphadenectomy @5 03`
C03	`03`	`X`	`SPA`	`@0 Linfadenectomía @5 03`
C03	`04`	`X`	`FRE`	`@0 Inguinal @5 04`
C03	`04`	`X`	`ENG`	`@0 Inguinal @5 04`
C03	`04`	`X`	`SPA`	`@0 Inguinal @5 04`
C03	`05`	`X`	`FRE`	`@0 Lymphoedème @5 07`
C03	`05`	`X`	`ENG`	`@0 Lymphedema @5 07`
C03	`05`	`X`	`SPA`	`@0 Linfedema @5 07`
C03	`06`	`X`	`FRE`	`@0 Complication @5 08`
C03	`06`	`X`	`ENG`	`@0 Complication @5 08`
C03	`06`	`X`	`SPA`	`@0 Complicación @5 08`
C03	`07`	`X`	`FRE`	`@0 Incidence @5 10`
C03	`07`	`X`	`ENG`	`@0 Incidence @5 10`
C03	`07`	`X`	`SPA`	`@0 Incidencia @5 10`
C03	`08`	`X`	`FRE`	`@0 Facteur prédictif @5 13`
C03	`08`	`X`	`ENG`	`@0 Predictive factor @5 13`
C03	`08`	`X`	`SPA`	`@0 Factor predictivo @5 13`
C03	`09`	`X`	`FRE`	`@0 Pronostic @5 17`
C03	`09`	`X`	`ENG`	`@0 Prognosis @5 17`
C03	`09`	`X`	`SPA`	`@0 Pronóstico @5 17`
C03	`10`	`X`	`FRE`	`@0 Homme @5 24`
C03	`10`	`X`	`ENG`	`@0 Human @5 24`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 24`
C03	`11`	`X`	`FRE`	`@0 Femelle @5 36`
C03	`11`	`X`	`ENG`	`@0 Female @5 36`
C03	`11`	`X`	`SPA`	`@0 Hembra @5 36`
C07	`01`	`X`	`FRE`	`@0 Appareil génital femelle pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Female genital diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato genital hembra patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Vulve pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Vulvar diseases @5 38`
C07	`02`	`X`	`SPA`	`@0 Vulva patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 53`
C07	`03`	`X`	`ENG`	`@0 Cardiovascular disease @5 53`
C07	`03`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 53`
C07	`04`	`X`	`FRE`	`@0 Lymphatique pathologie @5 54`
C07	`04`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 54`
C07	`04`	`X`	`SPA`	`@0 Linfático patología @5 54`
N21				`@1 337`

Format Inist (serveur)

NO :	PASCAL 01-0470242 INIST
ET :	Predictors of complications after inguinal lymphadenectomy
AU :	GOULD (Natalie); KAMELLE (Scott); TILLMANNS (Todd); SCRIBNER (Dennis); GOLD (Michael); WALKER (Joan); MANNEL (Robert)
AF :	Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center/Oklahoma City, Oklahoma 73190/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Gynecologic oncology; ISSN 0090-8258; Coden GYNOA3; Etats-Unis; Da. 2001; Vol. 82; No. 2; Pp. 329-332; Bibl. 14 ref.
LA :	Anglais
EA :	Objective. The aim of this study was to identify predictors of complications in patients undergoing inguinal lymphadenectomy (LND) in the treatment of vulvar carcinoma. Methods. Clinical information was abstracted from records of patients with invasive vulvar cancer. All patients underwent LND. Closed suction drains were placed in groin incisions and removed when output was less than 30 ml/24 h. Associations between variables were studied by X² and t tests. Results. Sixty-seven patients undergoing 112 LND were evaluated. Eighty-eight percent of patients underwent radical vulvar surgery and LND while 12% underwent LND alone. Patients were treated with either unilateral (22) or bilateral (45) LND. Seventy-three percent received extended postoperative prophylactic antibiotics. The median duration of suction drainage was 15 days for one drain and 14 days for two drains. Early postoperative cellulitis (<30 days after surgery) developed in 35.4%, early wound breakdown in 19.4%, early lymphedema in 4.8%, and early lymphocyst formation in 13.1%. Late cellulitis (>30 days after surgery) developed in 22.2%, late wound breakdown in 3.2%, late lymphedema in 29.5%, and late lymphocysts in 5%. Patients developing early cellulitis were more likely to have early wound breakdown (P = <0.001, RR 14.2) or early lymphocyst formation (P = 0.016, RR 7.6). Type of procedure, antibiotic use, need for adjuvant therapy, and duration of suction drainage did not influence early complications. Early complications and management strategies did not predict late complications. Conclusions. Chronic lymphedema occurs in nearly 30% of patients after LND. Late complications after LND were not predicted by early complications. New strategies for prevention of chronic lymphedema are needed.
CC :	002B25K
FD :	Tumeur maligne; Vulve; Lymphadénectomie; Inguinal; Lymphoedème; Complication; Incidence; Facteur prédictif; Pronostic; Homme; Femelle
FG :	Appareil génital femelle pathologie; Vulve pathologie; Appareil circulatoire pathologie; Lymphatique pathologie
ED :	Malignant tumor; Vulva; Lymphadenectomy; Inguinal; Lymphedema; Complication; Incidence; Predictive factor; Prognosis; Human; Female
EG :	Female genital diseases; Vulvar diseases; Cardiovascular disease; Lymphatic vessel disease
SD :	Tumor maligno; Vulva; Linfadenectomía; Inguinal; Linfedema; Complicación; Incidencia; Factor predictivo; Pronóstico; Hombre; Hembra
LO :	INIST-16044.354000099427810190
ID :	01-0470242

Links to Exploration step

Pascal:01-0470242

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Predictors of complications after inguinal lymphadenectomy</title>
<author><name sortKey="Gould, Natalie" sort="Gould, Natalie" uniqKey="Gould N" first="Natalie" last="Gould">Natalie Gould</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kamelle, Scott" sort="Kamelle, Scott" uniqKey="Kamelle S" first="Scott" last="Kamelle">Scott Kamelle</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tillmanns, Todd" sort="Tillmanns, Todd" uniqKey="Tillmanns T" first="Todd" last="Tillmanns">Todd Tillmanns</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Scribner, Dennis" sort="Scribner, Dennis" uniqKey="Scribner D" first="Dennis" last="Scribner">Dennis Scribner</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gold, Michael" sort="Gold, Michael" uniqKey="Gold M" first="Michael" last="Gold">Michael Gold</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Walker, Joan" sort="Walker, Joan" uniqKey="Walker J" first="Joan" last="Walker">Joan Walker</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mannel, Robert" sort="Mannel, Robert" uniqKey="Mannel R" first="Robert" last="Mannel">Robert Mannel</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0470242</idno>
<date when="2001">2001</date>
<idno type="stanalyst">PASCAL 01-0470242 INIST</idno>
<idno type="RBID">Pascal:01-0470242</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000829</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Predictors of complications after inguinal lymphadenectomy</title>
<author><name sortKey="Gould, Natalie" sort="Gould, Natalie" uniqKey="Gould N" first="Natalie" last="Gould">Natalie Gould</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kamelle, Scott" sort="Kamelle, Scott" uniqKey="Kamelle S" first="Scott" last="Kamelle">Scott Kamelle</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tillmanns, Todd" sort="Tillmanns, Todd" uniqKey="Tillmanns T" first="Todd" last="Tillmanns">Todd Tillmanns</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Scribner, Dennis" sort="Scribner, Dennis" uniqKey="Scribner D" first="Dennis" last="Scribner">Dennis Scribner</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gold, Michael" sort="Gold, Michael" uniqKey="Gold M" first="Michael" last="Gold">Michael Gold</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Walker, Joan" sort="Walker, Joan" uniqKey="Walker J" first="Joan" last="Walker">Joan Walker</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mannel, Robert" sort="Mannel, Robert" uniqKey="Mannel R" first="Robert" last="Mannel">Robert Mannel</name>
<affiliation><inist:fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Gynecologic oncology</title>
<title level="j" type="abbreviated">Gynecol. oncol.</title>
<idno type="ISSN">0090-8258</idno>
<imprint><date when="2001">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Gynecologic oncology</title>
<title level="j" type="abbreviated">Gynecol. oncol.</title>
<idno type="ISSN">0090-8258</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Complication</term>
<term>Female</term>
<term>Human</term>
<term>Incidence</term>
<term>Inguinal</term>
<term>Lymphadenectomy</term>
<term>Lymphedema</term>
<term>Malignant tumor</term>
<term>Predictive factor</term>
<term>Prognosis</term>
<term>Vulva</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Tumeur maligne</term>
<term>Vulve</term>
<term>Lymphadénectomie</term>
<term>Inguinal</term>
<term>Lymphoedème</term>
<term>Complication</term>
<term>Incidence</term>
<term>Facteur prédictif</term>
<term>Pronostic</term>
<term>Homme</term>
<term>Femelle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective. The aim of this study was to identify predictors of complications in patients undergoing inguinal lymphadenectomy (LND) in the treatment of vulvar carcinoma. Methods. Clinical information was abstracted from records of patients with invasive vulvar cancer. All patients underwent LND. Closed suction drains were placed in groin incisions and removed when output was less than 30 ml/24 h. Associations between variables were studied by X<sup>2</sup>
 and t tests. Results. Sixty-seven patients undergoing 112 LND were evaluated. Eighty-eight percent of patients underwent radical vulvar surgery and LND while 12% underwent LND alone. Patients were treated with either unilateral (22) or bilateral (45) LND. Seventy-three percent received extended postoperative prophylactic antibiotics. The median duration of suction drainage was 15 days for one drain and 14 days for two drains. Early postoperative cellulitis (<30 days after surgery) developed in 35.4%, early wound breakdown in 19.4%, early lymphedema in 4.8%, and early lymphocyst formation in 13.1%. Late cellulitis (>30 days after surgery) developed in 22.2%, late wound breakdown in 3.2%, late lymphedema in 29.5%, and late lymphocysts in 5%. Patients developing early cellulitis were more likely to have early wound breakdown (P = <0.001, RR 14.2) or early lymphocyst formation (P = 0.016, RR 7.6). Type of procedure, antibiotic use, need for adjuvant therapy, and duration of suction drainage did not influence early complications. Early complications and management strategies did not predict late complications. Conclusions. Chronic lymphedema occurs in nearly 30% of patients after LND. Late complications after LND were not predicted by early complications. New strategies for prevention of chronic lymphedema are needed.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0090-8258</s0>
</fA01>
<fA02 i1="01"><s0>GYNOA3</s0>
</fA02>
<fA03 i2="1"><s0>Gynecol. oncol.</s0>
</fA03>
<fA05><s2>82</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Predictors of complications after inguinal lymphadenectomy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>GOULD (Natalie)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KAMELLE (Scott)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TILLMANNS (Todd)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SCRIBNER (Dennis)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GOLD (Michael)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WALKER (Joan)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MANNEL (Robert)</s1>
</fA11>
<fA14 i1="01"><s1>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center</s1>
<s2>Oklahoma City, Oklahoma 73190</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>329-332</s1>
</fA20>
<fA21><s1>2001</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16044</s2>
<s5>354000099427810190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>14 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0470242</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Gynecologic oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective. The aim of this study was to identify predictors of complications in patients undergoing inguinal lymphadenectomy (LND) in the treatment of vulvar carcinoma. Methods. Clinical information was abstracted from records of patients with invasive vulvar cancer. All patients underwent LND. Closed suction drains were placed in groin incisions and removed when output was less than 30 ml/24 h. Associations between variables were studied by X<sup>2</sup>
 and t tests. Results. Sixty-seven patients undergoing 112 LND were evaluated. Eighty-eight percent of patients underwent radical vulvar surgery and LND while 12% underwent LND alone. Patients were treated with either unilateral (22) or bilateral (45) LND. Seventy-three percent received extended postoperative prophylactic antibiotics. The median duration of suction drainage was 15 days for one drain and 14 days for two drains. Early postoperative cellulitis (<30 days after surgery) developed in 35.4%, early wound breakdown in 19.4%, early lymphedema in 4.8%, and early lymphocyst formation in 13.1%. Late cellulitis (>30 days after surgery) developed in 22.2%, late wound breakdown in 3.2%, late lymphedema in 29.5%, and late lymphocysts in 5%. Patients developing early cellulitis were more likely to have early wound breakdown (P = <0.001, RR 14.2) or early lymphocyst formation (P = 0.016, RR 7.6). Type of procedure, antibiotic use, need for adjuvant therapy, and duration of suction drainage did not influence early complications. Early complications and management strategies did not predict late complications. Conclusions. Chronic lymphedema occurs in nearly 30% of patients after LND. Late complications after LND were not predicted by early complications. New strategies for prevention of chronic lymphedema are needed.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25K</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Vulve</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Vulva</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vulva</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lymphadénectomie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Lymphadenectomy</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Linfadenectomía</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Inguinal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Inguinal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Inguinal</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Complication</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Complication</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Complicación</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Incidence</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Incidence</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Incidencia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Facteur prédictif</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Predictive factor</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Factor predictivo</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>24</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Femelle</s0>
<s5>36</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Female</s0>
<s5>36</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hembra</s0>
<s5>36</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil génital femelle pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Female genital diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato genital hembra patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Vulve pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Vulvar diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Vulva patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>53</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>53</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Lymphatique pathologie</s0>
<s5>54</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>54</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>54</s5>
</fC07>
<fN21><s1>337</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 01-0470242 INIST</NO>
<ET>Predictors of complications after inguinal lymphadenectomy</ET>
<AU>GOULD (Natalie); KAMELLE (Scott); TILLMANNS (Todd); SCRIBNER (Dennis); GOLD (Michael); WALKER (Joan); MANNEL (Robert)</AU>
<AF>Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center/Oklahoma City, Oklahoma 73190/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Gynecologic oncology; ISSN 0090-8258; Coden GYNOA3; Etats-Unis; Da. 2001; Vol. 82; No. 2; Pp. 329-332; Bibl. 14 ref.</SO>
<LA>Anglais</LA>
<EA>Objective. The aim of this study was to identify predictors of complications in patients undergoing inguinal lymphadenectomy (LND) in the treatment of vulvar carcinoma. Methods. Clinical information was abstracted from records of patients with invasive vulvar cancer. All patients underwent LND. Closed suction drains were placed in groin incisions and removed when output was less than 30 ml/24 h. Associations between variables were studied by X<sup>2</sup>
 and t tests. Results. Sixty-seven patients undergoing 112 LND were evaluated. Eighty-eight percent of patients underwent radical vulvar surgery and LND while 12% underwent LND alone. Patients were treated with either unilateral (22) or bilateral (45) LND. Seventy-three percent received extended postoperative prophylactic antibiotics. The median duration of suction drainage was 15 days for one drain and 14 days for two drains. Early postoperative cellulitis (<30 days after surgery) developed in 35.4%, early wound breakdown in 19.4%, early lymphedema in 4.8%, and early lymphocyst formation in 13.1%. Late cellulitis (>30 days after surgery) developed in 22.2%, late wound breakdown in 3.2%, late lymphedema in 29.5%, and late lymphocysts in 5%. Patients developing early cellulitis were more likely to have early wound breakdown (P = <0.001, RR 14.2) or early lymphocyst formation (P = 0.016, RR 7.6). Type of procedure, antibiotic use, need for adjuvant therapy, and duration of suction drainage did not influence early complications. Early complications and management strategies did not predict late complications. Conclusions. Chronic lymphedema occurs in nearly 30% of patients after LND. Late complications after LND were not predicted by early complications. New strategies for prevention of chronic lymphedema are needed.</EA>
<CC>002B25K</CC>
<FD>Tumeur maligne; Vulve; Lymphadénectomie; Inguinal; Lymphoedème; Complication; Incidence; Facteur prédictif; Pronostic; Homme; Femelle</FD>
<FG>Appareil génital femelle pathologie; Vulve pathologie; Appareil circulatoire pathologie; Lymphatique pathologie</FG>
<ED>Malignant tumor; Vulva; Lymphadenectomy; Inguinal; Lymphedema; Complication; Incidence; Predictive factor; Prognosis; Human; Female</ED>
<EG>Female genital diseases; Vulvar diseases; Cardiovascular disease; Lymphatic vessel disease</EG>
<SD>Tumor maligno; Vulva; Linfadenectomía; Inguinal; Linfedema; Complicación; Incidencia; Factor predictivo; Pronóstico; Hombre; Hembra</SD>
<LO>INIST-16044.354000099427810190</LO>
<ID>01-0470242</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000829 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000829 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:01-0470242
   |texte=   Predictors of complications after inguinal lymphadenectomy
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Predictors of complications after inguinal lymphadenectomy

Predictors of complications after inguinal lymphadenectomy

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri